The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
Open accessAbstract
Objectives The purpose of this study was to estimate the effect of long-term exposure to lower plasma low-density lipoprotein cholesterol (LDL-C) on the risk of coronary heart disease (CHD).Background LDL-C is causally related to the risk of CHD. However, the association between long-term exposure to lower LDL-C beginning early in life and the risk of CHD has not been reliably quantified.Methods We conducted a series of meta-analyses to estimate the effect of long-term exposure to lower LDL-C on the risk of CHD mediated by 9 polymorphisms in 6 different genes. We then combined these Mendelian randomization studies in a meta-analysis to obtain a more precise estimate of the effect of long-term exposure to lower LDL-C and compared it with the clinical benefit associated with the same magnitude of LDL-C reduction during treatment with a statin.Results All 9 polymorphisms were associated with a highly consistent reduction in the risk of CHD per unit lower LDL-C, with no evidence of heterogeneity of effect (I(2) = 0.0%). In a meta-analysis combining nonoverlapping data from 312,321 participants, naturally random allocation to long-term exposure to lower LDL-C was associated with a 54.5% (95% confidence interval: 48.8% to 59.5%) reduction in the risk of CHD for each mmol/l (38.7 mg/dl) lower LDL-C. This represents a 3-fold greater reduction in the risk of CHD per unit lower LDL-C than that observed during treatment with a statin started later in life (p = 8.43 × 10(-19)).Conclusions Prolonged exposure to lower LDL-C beginning early in life is associated with a substantially greater reduction in the risk of CHD than the current practice of lowering LDL-C beginning later in life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, genetic variants reflect the effect of lifelong changes in ApoB-containing lipoproteins on the risk of cardiovascular disease, which appear to be cumulative over time.5,34”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredIn the citing paper
“Numerous epidemiological studies, Mendelian randomization studies, and RCTs have consistently demonstrated a log-linear relationship between the absolute changes in plasma LDL-C and the risk of ASCVD [34,45-50].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [47]
In the citing paper
“Additionally, increasing evidence also suggests that the duration of exposure to low LDL-C levels may be as important as the magnitude of LDL-C lowering [11][12][13][14][15][16].”
In the citing paper
“A large meta-analysis by Ference et al. has demonstrated that prolonged exposure to lower LDL-C levels beginning at a young age is associated with a substantially greater reduction in the risk of CVD than the current practice of lowering LDL-C levels later in life [13].”
In the citing paper
“It was found that lifelong exposure to low LDL-C levels as a result of these gene polymorphisms was associated with three-fold greater reduction in the risk of CVD per unit lower LDL-C level than that observed during treatment with a statin started later in life.”
In the citing paper
“The long-term follow-up of large clinical trials of statins that were conducted in the 1990s, such as the West of Scotland Coronary Prevention Study (WOSCOPS) and the Heart Protection Study (HPS)628, 629) confirmed that early initiation of LDLC-lowering therapy regardless of the plasma LDL-C level was useful for the long-term prevention of cardiovascular events and all-cause mortality in high-risk”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [628]
In the citing paper
“No increases in new-incidence cancer or non-CVD deaths were observed, which reconfirms the safety of long-term LDL-C-lowering therapy using statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [628]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies (2011) · Nature · doi:10.1038/nature10405 · Cited by 2,033
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 901
Lee, M. G. Y., Naimo, P. S., Koshy, A. N., Buratto, E., WILSON, W. M., Grigg, L., Joshi, S. B., & English, K. M. (2024) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2024.100561 · Cited by 3
Prabhakar, A. P., Vedamurthy, D., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00764-x · Cited by 3
Worledge, E., Billups, S. J., Titus, O., & Saseen, J. J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.186 · Cited by 3
Big data and cardiovascular risk—insights into obesity, diabetes, and coronary heart disease
Dörr, M. (2025) · Herz · doi:10.1007/s00059-025-05323-z · Cited by 4
Wan, K., Wang, R., Yan, H., Cheng, W., Ma, F., Jin, Y., & Wang, R. (2025) · BMC Public Health · doi:10.1186/s12889-025-24568-1 · Cited by 3
Hwang, S., Karhunen, V., Patel, A., Lockhart, S. M., Carter, P., Whittaker, J. C., & Burgess, S. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf223 · Cited by 3
Atherosclerosis: Is a cure in sight?
Wilson, D. P., & Gidding, S. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.06.010 · Cited by 3
Statins and PCSK9 Inhibitors: Defining the Correct Patients
Farnier, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_9 · Cited by 3
Wang, X., Song, X.-L., Zhang, Y., Luo, G., Tai, H., Lin, Z., Zhu, P., Sun, N., Chu, Z.-S., Yu, Z., et al. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/8858962 · Cited by 3
Cefalu, A. B., Spina, R., Noto, D., Rabacchi, C., Giammanco, A., Simone, M. L., Brucato, F., Scrimali, C., Gueli-Alletti, M. G., Barbagallo, C. M., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.04.009 · Cited by 3
Cefalu, A. B., Garbelotto, R., Mombelli, G. G., Pirro, M., Rubba, P., Arca, M., Borghi, C., Bonomo, K., Gonnelli, S., Massaroni, K., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.020 · Cited by 3
Xu, L., Sun, M., Qi, H., Ju, C., Chen, Z., Gao, X., & Lin, Z. (2022) · Metabolites · doi:10.3390/metabo12121276 · Cited by 3
Luca, L. D., Riccio, C., Navazio, A., Valente, S., Cipriani, M., Corda, M., Nardo, A. D., Francese, G. M., Napoletano, C., Tizzani, E., et al. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad100 · Cited by 3
Meng, X., Chen, B., Liu, X.-W., Zhang, J., Xie, S., Liu, L., Wen, L.-F., Deng, A., & Mao, Z. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01376-9 · Cited by 3
The association between rapid growth and lipid profile: a systematic review and meta-analysis
Chen, B., Chen, Y., Wang, Y., Xin, Q., & Ma, D. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1353334 · Cited by 3
Zhao, Y., Yang, H., Li, H., Liang, S., Wang, M., Li, C., Zhuo, D., Fan, F., Guo, M., Lv, X., et al. (2024) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2024.109905 · Cited by 3
Olatunji, G. D., Kokori, E., Moradeyo, A. A., Lema, K. F., Ayo, O. R., Obasanjo, O. M., Mustapha, M. J., Stanley, A. C., & Aderinto, N. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00335-3 · Cited by 3
Dalakoti, M., & Virani, S. S. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100720 · Cited by 3
Influence of Persistently Elevated LDL Values on Carotid Intima Media Thickness in Elite Athletes
Gioia, G. D., Buzzelli, L., Ferrera, A., Maestrini, V., Squeo, M. R., Lemme, E., Monosilio, S., Serdoz, A., & Pelliccia, A. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00698-2 · Cited by 3
Mehilli, J., Eckardt, L., Laufs, U., Boer, J., Birkemeyer, R., Frantz, S., Schächinger, V., Mahfoud, F., Perings, C., Ghanem, A., et al. (2025) · Die Kardiologie · doi:10.1007/s12181-025-00744-w · Cited by 3
Preventing atherosclerosis: rethinking the starting line
Shapiro, M. D., & Yang, E. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf479 · Cited by 3
Werba, J. P., Vigo, L., Veglia, F., Marenzi, G., Tremoli, E., & Baldassarre, D. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1436 · Cited by 3
Clinical Application of Genetic Prediction in the Management of CAD
Roberts, R., & Fair, J. (2021) · International Journal of Innovative Research in Medical Science · doi:10.23958/ijirms/vol06-i01/1025 · Cited by 3
deGoma, E. M., Salavati, A., Shinohara, R. T., Saboury, B., Pollan, L. J., Schoen, M. A., Torigian, D. A., Mohler, E. R., Dunbar, R. L., Litt, H. I., et al. (2015) · Academic Radiology · doi:10.1016/j.acra.2014.12.015 · Cited by 3
Gaisenok, O. V., Rozhkov, A. N., & Лишута, А. С. (2018) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2018-14-3-434-440 · Cited by 3
Yelnik, C., & Bruckert, É. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.11.007 · Cited by 4
Weir (2020) · The Journal of Family Practice · doi:10.12788/jfp.0068 · Cited by 3
Recognition and Management of Hypoglycemia
Shubrook (2020) · The Journal of Family Practice · doi:10.12788/jfp.0069 · Cited by 3
Bempedoic Acid: A New Avenue for the Treatment of Dyslipidemia
Smith, W., Cheng-Lai, A., & Nawarskas, J. J. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000401 · Cited by 3
Physical activity level (PAL) and risk factors of cardiovascular disease in the MASHAD study cohort
Sadabadi, F., Zirak, R. G., Ghazizadeh, H., Rohban, M., Moghadam, A. R., Mouhebati, M., Ehyaei, S., Fadihe, F. T., Zare‐Feyzabadi, R., Ferns, G. A., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102316 · Cited by 3
Ditaranto, R., Vitale, G., Lorenzini, M., & Rapezzi, C. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz030 · Cited by 3
Brotherhood of genetics and preventive medication: Figure 1
Schunkert, H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv153 · Cited by 3
The New Cholesterol Guidelines
Vogel, R. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1168 · Cited by 3
Sobczyk, M. K., Zheng, J., Smith, G. D., & Gaunt, T. R. (2022) · medRxiv · doi:10.1101/2022.04.11.22273633 · Cited by 3
Ference, B. A., Ference, T. B., Catapano, A. L., Nicholls, S. J., & Ray, K. K. (2024) · medRxiv · doi:10.1101/2024.06.30.24309740 · Cited by 3
Self-citationMendelian randomisation with proxy exposures: challenges and opportunitiesPreprint
Rahu, I., Tambets, R., Fauman, E. B., & Alasoo, K. (2024) · medRxiv · doi:10.1101/2024.10.21.24315891 · Cited by 3
Laufs, U., Custodis, F., & Werner, C. M. (2016) · Herz · doi:10.1007/s00059-016-4429-1 · Cited by 3
Rosman, N., Nawawi, H. M., Al-Khateeb, A., Chua, Y.-A., & Chua, A.-L. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.10.006 · Cited by 2
Ashburn, N. P., Snavely, A. C., Ehrig, M. R., Shapiro, M. D., Herrington, D. M., Reboussin, D. M., Gesell, S. B., & Mahler, S. A. (2025) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000390 · Cited by 2
Body Mass Index as an Example of a Negative Confounder: Evidence and Solutions
Jiesisibieke, Z. L., & Schooling, C. M. (2025) · Genes · doi:10.3390/genes16050564 · Cited by 3
Chen, V., Chiavaroli, L., Glenn, A. J., Kavanagh, M. E., Zeitoun, T., Mahdavi, S. M., Kendall, C. W. C., Jenkins, D. J. A., El‐Sohemy, A., & Sievenpiper, J. L. (2025) · BMC Public Health · doi:10.1186/s12889-025-22479-9 · Cited by 3
Zhang, M., Jiang, Y., Lu, P., Shen, Z., Gao, X. Y., & Wang, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c11879 · Cited by 2
Increased high-risk plaque burden in type 2 diabetes: a 10-year follow-up study
Gaillard, E. L., Cramer, S. H. M., Hanssen, N. M. J., Bom, M. J., Chamuleau, S. A. J., Planken, R. N., Choi, A., Boekholdt, S. M., Stroes, E. S. G., Knaapen, P., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02977-1 · Cited by 3
Vázquez-Martínez, V. H., Martínez-Bautista, H., Muñoz‐Villegas, P., Morales, J. I. L., & Salazar, M. D. R. P. (2025) · Medical Sciences · doi:10.3390/medsci13040240 · Cited by 2
Hossain, M. B., Amin, R., & Uddin, M. J. (2024) · TAJ Journal of Teachers Association · doi:10.70818/taj.v037i02.0552 · Cited by 2
Jin, M., Zhou, Y., Zhao, X., Liu, C., Liu, Z., Liu, S., & Zhenyan, F. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05502-8 · Cited by 2
Sun, Q., & Yu, L. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113127 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Twenty-five years of statins: where do we go from here?
Gotto, A. M., & Moon, J. E. (2015) · Clinical Lipidology · doi:10.2217/clp.14.62 · Cited by 2
da Silva, P. M. (2013) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2012.12.006 · Cited by 2
da Silva, P. M. (2013) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2013.04.009 · Cited by 2
Laufs, U. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_3 · Cited by 2
Time for new low density lipoprotein cholesterol (LDL-C) targets?
Daskalopoulou, S. S., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369957 · Cited by 2
Epidemiology of Atherosclerotic Cardiovascular Disease
Hirahatake, K. M., Dicklin, M. R., & Maki, K. C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_5 · Cited by 2
Universal Pediatric Cholesterol Screening: The Time Has Come!
McGowan, M. P., & Peterson, A. L. H. (2024) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2024.113928 · Cited by 2
Updates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 4
Natale, F., Franzese, R., Marotta, L., Mollo, N., Solimene, A., Luisi, E., Gentile, C., Loffredo, F. S., Golino, P., & Cimmino, G. (2024) · Life · doi:10.3390/life14060679 · Cited by 2
Yan, X., Wang, J., Zhou, Y., Yang, Z., Wang, B., Jiang, L., Zhang, L., Kou, Z., Song, J., & Li, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04393-0 · Cited by 2
Kiratipaisarl, W., Surawattanasakul, V., Sirikul, W., & Phinyo, P. (2025) · BMJ Health & Care Informatics · doi:10.1136/bmjhci-2024-101180 · Cited by 2
Reflections on metabolic syndrome in children
Hirschler, V. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12704 · Cited by 2
Opposing View: A Blind Faith in Meta-Analyses in Academia Could Be a Threat to Public Health
Bae, J. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.308 · Cited by 3
Gondolatok a plakkokról és az élethosszig tartó lipidcsökkentésről
Márk, L., Barna, I., & Kiss, R. G. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.2.161 · Cited by 2
DuBroff, R. J. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.01.004 · Cited by 2
Plasma urate and coronary heart disease: fingerprint match, but no smoking gun
Burgess, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00425-8 · Cited by 2
Reducing exposure to cardiovascular risk factors: the legacy of prevention
Arsenault, B. J., & Puri, R. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.08.83 · Cited by 2
The year in cardiology 2015: prevention.
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016) · Cardiologia Croatica · doi:10.15836/ccar2016.218 · Cited by 2
The Basis of Atherosclerotic Guidelines—Time for a Change?
Schade, D. S., & Eaton, R. P. (2018) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2018.87033 · Cited by 2
Risk factor profile in young adults with early coronary artery disease and abdominal obesity
Ragino, Y. I., Kuzminykh, N. A., Oblaukhova, V. I., Шрамко, В. С., Вахтанговна, Д. Д., & Щербакова, Л. В. (2020) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2020-9-2-64-73 · Cited by 3
Updated management of dyslipidaemia in diabetes: A new step towards more stringent targets
Monnier, L., Schlienger, J.-L., & Colette, C. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100001 · Cited by 2
Pediatric dyslipidemias: lipoprotein metabolism disorders in children
Ballout, R. A., & Remaley, A. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817962-8.00002-0 · Cited by 3
Update Fettstoffwechselstörungen
Parhofer, K. G. (2013) · Der Internist · doi:10.1007/s00108-013-3335-3 · Cited by 2
Monnier, L., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.12.006 · Cited by 2
The Association Between Dyslipidemia and Its Treatment with Erectile Dysfunction
Pittaras, A. E., Avranas, K., Imprialos, K. P., Faselis, C. J., & Kokkinos, P. F. (2014) · Springer eBooks · doi:10.1007/978-3-319-08272-1_13 · Cited by 2
Treatment of atherogenic dyslipidemia: modern principles and new possibilities
Bubnova, M. G. (2017) · Cardiosomatics · doi:10.26442/2221-7185_8.2.51-58 · Cited by 2
Effect of Long-Term Low Lipoproteins on Neurocognitive Function
Verbeek, R., Boekholdt, S. M., Luben, R., Stroes, E. S. G., Khaw, K., & Hovingh, G. K. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.043 · Cited by 2
Prinzip der mendelschen Randomisierung und Anwendung in der kardiovaskulären Medizin
Katzmann, J. L., Ference, B. A., & Laufs, U. (2019) · Der Kardiologe · doi:10.1007/s12181-019-0328-z · Cited by 2
Self-citation¿Es útil calcular el riesgo cardiovascular a 30 años?
Díaz, F. J. H., & Ruilope, L. M. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.01.020 · Cited by 2
Urbut, S., Yeung, M. W., Khurshid, S. S., Cho, S. M. J., Schuermans, A., German, J., Taraszka, K., Fahed, A. C., Ellinor, P. T., Trinquart, L., et al. (2023) · medRxiv · doi:10.1101/2023.11.08.23298229 · Cited by 2
Role of Xenosterols in Health and Disease
Kanuri, B., Fong, V., & Patel, S. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00024-5 · Cited by 1
Monnier, L., Schlienger, J.-L., & Colette, C. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.015 · Cited by 1
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Li, Q., Mu, Z., Dong, Y., Ouyang, Z., Zuo, J., Wu, Y., Yang, Y., Sun, S., Liang, H., & Bai, L. (2025) · Angewandte Chemie · doi:10.1002/ange.202502559 · Cited by 1
Childhood Cholesterol Screening Is Not Cost-Effective
Gillman, M. W. (2025) · JAMA · doi:10.1001/jama.2025.20945 · Cited by 1
Landolfo, M., Gezzi, A., Spannella, F., Giulietti, F., Alborino, F., Massini, L. S., & Sarzani, R. (2025) · BMC Medicine · doi:10.1186/s12916-025-04552-7 · Cited by 1
Howe, L. J., Aulchenko, Y. S., Smith, G. D., Davies, N. M., Esparza-Gordillo, J., Johnson, T., Liu, J. Z., Richardson, T. G., Sanséau, P., Scott, R. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67199-1 · Cited by 2
Koychev, I. G., Vaci, N., Moonen, J. E. F., Reid, G., Howgego, G., Yaffe, K. S., Nasrallah, I. M., Sidney, S. S., Jindra, C., Gallacher, J., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251401482 · Cited by 1
Genetic evidence supports therapeutic modulation of progranulin levels in Alzheimer’s Disease
Robins, C., Eicher, J. D., Liu, J., Lo, Y., Richardson, T. G., Western, D., Davitte, J., Cruchaga, C., Initiative, A. D. N., Kumar, U., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00011-y · Cited by 1
Shawki, M., Weerasooriya, N., Salib, A., Al-Fiadh, H., Zoumberis, C., Sanders, K., Weerasooriya, S., & Al-Fiadh, A. H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020832 · Cited by 1
Prevención lipídica en la diabetes tipo 1: del riesgo estimado al riesgo acumulado
Miñambres, I., & Pérez, A. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2026.500894 · Cited by 1
Rethinking Cholesterol Management in Women
Honigberg, M. C. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.002 · Cited by 1
Ray, K. K., Aguiar, C., Arca, M., Connolly, D. L., Eriksson, M., Ferrières, J., Laufs, U., Mostaza, J., Nanchen, D., Boachie, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101577 · Cited by 1
Wang, N., Guo, K., Zhu, B., Zhang, Y., Jia, X., Liu, Y., Di, Z., Gu, N., & Li, T. (2026) · PeerJ · doi:10.7717/peerj.20968 · Cited by 1
Kim, S. R., Kim, M., Kim, H., Cho, D. H., Kim, H.-L., Kim, Y., Na, J. O., Yoon, H., Shin, M. S., Kim, M., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2025.0262 · Cited by 1
LDL-Cholesterol Lowering Therapies: An Update
Humphrey, R., & Bowman, L. J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53219 · Cited by 2
Atherosclerosis and dementia - causal aspects and preventive potential
Rasmussen, I. J., Luo, J., Rasmussen, K. L., Kjeldsen, E. W., Schneider, L. S., Sandau, N., Thomassen, J. Q., & Frikke‐Schmidt, R. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120745 · Cited by 2
Khattib, A., Shmet, M., Ashkar, R., Hayek, T., & Khatib, S. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001047 · Cited by 1
LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions
Palloni, M. C., Farella, T., Faggiano, A., Vatri, M., Fattirolli, F., Angelino, E., Ambrosetti, M., Ruscica, M., Corsini, A., Carugo, S., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100574 · Cited by 1
Sinning, D., & Landmesser, U. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag456 · Cited by 1
Genetic Epidemiology of Atherosclerotic Vascular Disease
O’Donnell, C. J., & Fu, Y. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_47 · Cited by 1
Windler, E. E. T., & Zyriax, B. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.027 · Cited by 1
Metadata
- Authors
- Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M.
- Affiliations
- Wayne State University (US)
- University of Tennessee Health Science Center (US)
- Detroit Medical Center (US)
- Corresponding author
- Ference, Brian A.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 60
- Issue
- 25
- Pages
- 2631-2639
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W72392028
- Cited by
- 898
- References
- 44
- Citations by year
- 2026: 69 · 2025: 61 · 2024: 65 · 2023: 80 · 2022: 64 · 2021: 69 · 2020: 81 · 2019: 74 · 2018: 55 · 2017: 48 · 2016: 82 · 2015: 67 · 2014: 41 · 2013: 37 · 2012: 2
- FWCI
- 47.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- Medtronic
- NIH
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- LDL cholesterol, coronary heart disease risk, genetic polymorphism, Mendelian randomization, statin therapy, LDL cholesterol lowering, cardiovascular risk reduction
- MeSH terms
- Coronary Artery Disease, Follow-Up Studies, Genetic Markers, Humans, Cholesterol, LDL, Polymorphism, Genetic, Risk Factors, Time Factors, Global Health, Incidence, Risk Assessment, Genetic Predisposition to Disease, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
